Shanghai OPM Biosciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Zhihua Xiao
Chief executive officer
CN¥1.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.2yrs |
| CEO ownership | 24.9% |
| Management average tenure | no data |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
After Leaping 47% Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) Shares Are Not Flying Under The Radar
Nov 21
Weak Statutory Earnings May Not Tell The Whole Story For Shanghai OPM Biosciences (SHSE:688293)
Nov 07Shanghai OPM Biosciences' (SHSE:688293) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 06Optimistic Investors Push Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) Shares Up 28% But Growth Is Lacking
Mar 04CEO
Zhihua Xiao (50 yo)
4.2yrs
Tenure
CN¥1,650,600
Compensation
Dr. Zhihua Xiao is General Manager & Chairman of the Board of Shanghai OPM Biosciences Co., Ltd. from October 14, 2020. Dr. Xiao was Founder, Chairman, & General manager of Opmai Biosciences until 2020.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 4.2yrs | CN¥1.65m | 24.86% CN¥ 1.1b | |
| CFO, Secretary | 5.6yrs | CN¥1.42m | 0.0098% CN¥ 425.5k | |
| Supervisor | 4.2yrs | no data | no data | |
| Director | 4.2yrs | no data | no data |
4.2yrs
Average Tenure
47yo
Average Age
Experienced Board: 688293's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 19:24 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai OPM Biosciences Co., Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiabo Zhang | Guosen Securities Co., Ltd. |
| Wenxin Yu | Haitong International Research Limited |
| Kehan Meng | Haitong International Research Limited |